Discovering Anti-Cancer Drugs via Computational Methods

被引:197
作者
Cui, Wenqiang [1 ,2 ]
Aouidate, Adnane [1 ]
Wang, Shouguo [1 ]
Yu, Qiuliyang [1 ]
Li, Yanhua [2 ]
Yuan, Shuguang [1 ]
机构
[1] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen, Peoples R China
[2] Northeast Agr Univ, Coll Vet Med, Harbin, Peoples R China
关键词
anti-cancer; CADD; drug discovery; AI; computational methods; SUPERVISED MOLECULAR-DYNAMICS; GROWTH-FACTOR RECEPTOR; TARGET INTERACTION PREDICTION; PROTEIN-COUPLED RECEPTORS; C-MET; PHARMACOPHORE MODEL; NEURAL-NETWORKS; INHIBITOR; CANCER; HSP90;
D O I
10.3389/fphar.2020.00733
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
New drug discovery has been acknowledged as a complicated, expensive, time-consuming, and challenging project. It has been estimated that around 12 years and 2.7 billion USD, on average, are demanded for a new drug discovery via traditional drug development pipeline. How to reduce the research cost and speed up the development process of new drug discovery has become a challenging, urgent question for the pharmaceutical industry. Computer-aided drug discovery (CADD) has emerged as a powerful, and promising technology for faster, cheaper, and more effective drug design. Recently, the rapid growth of computational tools for drug discovery, including anticancer therapies, has exhibited a significant and outstanding impact on anticancer drug design, and has also provided fruitful insights into the area of cancer therapy. In this work, we discussed the different subareas of the computer-aided drug discovery process with a focus on anticancer drugs.
引用
收藏
页数:14
相关论文
共 134 条
[101]   A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction [J].
Rush, TS ;
Grant, JA ;
Mosyak, L ;
Nicholls, A .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (05) :1489-1495
[102]  
Sabbadin D, 2014, J CHEM INF MODEL, V54, P372, DOI [10.1021/ci4007t6b, 10.1021/ci400766b]
[103]   Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview [J].
Salmaso, Veronica ;
Moro, Stefano .
FRONTIERS IN PHARMACOLOGY, 2018, 9
[104]   Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement [J].
Schwab, Richard ;
Petak, Istvan ;
Kollar, Mihaly ;
Pinter, Ferenc ;
Varkondi, Edit ;
Kohanka, Andrea ;
Barti-Juhasz, Helga ;
Schoenleber, Julia ;
Brauswetter, Diana ;
Kopper, Laszlo ;
Urban, Laszlo .
LUNG CANCER, 2014, 83 (01) :109-111
[105]   Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study [J].
Shaik, Naveed ;
Hee, Brian ;
Wei, Hua ;
LaBadie, Robert R. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (03) :463-472
[106]   Inhibitors of the HSP90 molecular chaperone: Current status [J].
Sharp, Swee ;
Workman, Paul .
ADVANCES IN CANCER RESEARCH, VOL 95, 2006, 95 :323-348
[107]   In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors [J].
Sharp, Swee Y. ;
Boxall, Kathy ;
Rowlands, Martin ;
Prodromou, Chrisostomos ;
Roe, S. Mark ;
Maloney, Alison ;
Powers, Marissa ;
Clarke, Paul A. ;
Box, Gary ;
Sanderson, Sharon ;
Patterson, Lisa ;
Matthews, Thomas P. ;
Cheung, Kwai-Ming J. ;
Ball, Karen ;
Hayes, Angela ;
Raynaud, Florence ;
Marais, Richard ;
Pearl, Laurence ;
Eccles, Sue ;
Aherne, Wynne ;
McDonald, Edward ;
Workman, Paul .
CANCER RESEARCH, 2007, 67 (05) :2206-2216
[108]   Encorafenib and Binimetinib: First Global Approvals [J].
Shirley, Matt .
DRUGS, 2018, 78 (12) :1277-1284
[109]   Cemiplimab effective in cutaneous SCC [J].
Sidaway, Peter .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (08) :472-472
[110]   Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors [J].
Smith, Nicola F. ;
Hayes, Angela ;
James, Karen ;
Nutley, Bernard P. ;
McDonald, Edward ;
Henley, Alan ;
Dymock, Brian ;
Drysdale, Martin J. ;
Raynaud, Florence I. ;
Workman, Paul .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (06) :1628-1637